Eli Lil­ly makes mod­est bet on 'all-in-hu­man' dis­cov­ery out­fit for ALS drugs, deep­en­ing bid in pre­ci­sion neu­rol­o­gy

For years, Big Phar­ma has re­treat­ed from neu­rol­o­gy amid a se­ries of high-pro­file fail­ures in the big-tick­et in­di­ca­tions such as Alzheimer’s and ALS. But the tide has turned in re­cent years, and big drug­mak­ers like Eli Lil­ly have dou­bled down on their in­vest­ments in the space.

Now, look­ing to crack a new path to “pre­ci­sion neu­rol­o­gy,” Lil­ly is putting its name be­hind a ge­nomics play­er aim­ing for a nov­el path to neu­ro­log­i­cal dis­ease ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER